BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 3, 2020
View Archived Issues
SAB initiates phase I trial of SAB-176 for treatment of seasonal influenza
Read More
Fish model identifies druggable osteoporosis targets
Read More
Tryptophan metabolites keep gut barrier strong
Read More
First mouse-adapted strain of SARS-CoV-2
Read More
Novel radioimmunotherapeutic shows promise for clear cell renal cell carcinoma
Read More
Phenex-FXR patents new oxysterol receptor inverse agonists
Read More
Theralase updates on phase II study of TLD-1433 plus TLC-3200 in non-muscle-invasive bladder cancer
Read More
Vertex Pharmaceuticals synthesizes new analgesic drugs
Read More
Calithera Biosciences identifies arginase inhibitors
Read More
Accro Bioscience patent describes necrosis inhibitors
Read More
WARF presents new antifungal compounds
Read More
Phase Ib efficacy assessment of ETC-159 begins in patients with cancer
Read More
Phase III trial approved for RHB-204 for nontuberculous mycobacteria infections
Read More
Recruitment underway for trial of Roche's RO-7248824 in Angelman syndrome
Read More
First-in-human trial of BNT-411 underway in solid tumor and lung cancer patients
Read More
Endothelial-specific form of type 18 collagen COL-18N is a marker of hemophilic arthropathy
Read More
Primary endpoint met with IMU-838 in phase II relapsing-remitting multiple sclerosis trial
Read More
Innovent Biologics commences phase I trial of IBI-322 in advanced cancer
Read More
FDA approves Epidiolex for seizures in tuberous sclerosis complex
Read More
MorphoSys receives FDA approval for Monjuvi for diffuse large B-cell lymphoma
Read More
Data presented for OGA inhibitor LY-3372689 in healthy subjects
Read More
Cosentyx approved in the E.U. for pediatric psoriasis
Read More
Rozlytrek approved in E.U. for NTRK fusion solid tumors and for ROS1-positive advanced NSCLC
Read More